Locations
Ohio, USA · Cleveland, OH, USA
industry
Health · Medical Devices
Size
1 - 10 employees
Stage
Other
founded in
2012
Our mission is to decentralize access to cardiovascular care in real time. VPExam helps detect cardiac abnormalities and decompensation early on by offering real-time data through augmented reality exams combined with Artificial Intelligence-based alerts. This enables cardiologists to provide prompt and effective interventions with fewer hospitalizations and better overall quality of care. We bring virtual cardiology care everywhere. Heart failure is a rapidly growing problem for the entire healthcare system. We partner with cardiologists to improve the lives of their patients by overcoming barriers of traditional telemedicine utilizing optimized virtual care workflows. Virtual physical exams customized by your own physician and guided by Augmented Reality (AR) can be completed with minimal experience by nurses, medical assistants, technicians, family members, or patients themselves. These encounters can occur far beyond the walls of the hospital including skilled nursing facilities, pharmacies, or in the patient’s own home during home care visits. VPExam is device agnostic. We partner with a variety of medical-grade device manufacturers including Bluetooth stethoscopes with electrocardiograms guided by augmented reality to bring your doctor to the bedside. VPExam integrates with Apple Health, Google Fit, and other biometric Bluetooth devices to create customizable Artificial Intelligence alerts that can go directly to the care team via email, text, or EMR alerts. More than simple remote patient monitoring, these alerts act as triggers to deploy VPExam technology and services directly to the patients without the need to bring them to the office, emergency room, or hospital. We are able to minimize both geographic and financial barriers to guideline-directed cardiovascular care. VPExam also resulted in over a 40% relative risk reduction in 30-day re-hospitalization and over a 56% relative risk reduction in 30-day all-cause mortality for heart failure patients.
Something looks off?